NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma

Autor: M. Reig, S. Damian, D. Roberti, S. Maruzzelli, P. Crivori, L. Gianellini, M.T. De Pietro, N. Personeni, M. Sanduzzi-Zamparelli, M. Duca, L. Disconzi, A. Montagnoli, A. Galvani, E. Ardini, A. Isacchi, E. Colajori, C. Davite, L. Mahnke, L. Rimassa

Publikováno v: European Journal of Cancer. 174:S2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8129df81421324ef8a21359e138265b3
https://doi.org/10.1016/s0959-8049(22)00813-9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Autor: R. C. Coombes, Monica Castiglione, L. Del Mastro, Cjh van de Velde, Olaf Ortmann, Alan S. Coates, Stephen E. Jones, Emma Hall, Emilio Bajetta, Per Eystein Lønning, M. Carpentieri, M Subar, E Colajori, Lucy Kilburn, Thierry Delozier, N Stuart, K Diedrich, G. Cocconi, D. Dodwell, Stig Holmberg, Robert Paridaens, R. G. Bogle, Judith M Bliss, Alan L Stewart, Lesley Fallowfield, Claire Snowdon, Jacek Jassem, Robert E. Coleman, John F. Forbes, Isabel Alvarez, Gianfilippo Bertelli, E. Ireland, Elizabeth Mickiewicz, Jens O. Andersen

Publikováno v: Coombes, R C, Kilburn, L S, Snowdon, C F, Paridaens, R, Coleman, R E, Jones, S E, Jassem, J, Van de Velde, C J H, Delozier, T, Alvarez, I, Del Mastro, L, Ortmann, O, Diedrich, K, Coates, A S, Bajetta, E, Holmberg, S B, Dodwell, D, Mickiewicz, E, Andersen, J, Lønning, P E, Cocconi, G, Forbes, J, Castiglione, M, Stuart, N, Stewart, A, Fallowfield, L J, Bertelli, G, Hall, E, Bogle, R G, Carpentieri, M, Colajori, E, Subar, M, Ireland, E, Bliss, J M & Intergroup Exemestane Study 2007, ' Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. ', Lancet, vol. 369, no. 9561, pp. 559-70 . https://doi.org/10.1016/S0140-6736(07)60200-1

BACKGROUND: Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, litt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c925ed5368ece6d83201a940b723e5a
https://pure.au.dk/portal/da/publications/survival-and-safety-of-exemestane-versus-tamoxifen-after-23-years-tamoxifen-treatment-intergroup-exemestane-study-a-randomised-controlled-trial(a45ed300-e8fd-11dc-9afb-000ea68e967b).html

Subject Index 1993

Autor: H. Kleinau, R. Engelhardt, T. Chan, S. Kerpel-Fronius, A. Engert, A. Obermair, K. Czerwenka, E. May, W. Gassmann, V. Diehl, W. Scheithauer, E. Hagmüller, H. Henss, C. Kurz, S. Seeber, G.G.T.Y. Chen, A. Schomburg, P. Ray, M. Löffler, M. Pfreundschuh, P.M. Schlag, M. Matthias, W. Hunstein, J. Boese-Landgraf, K. Haider, S. Vijayakumar, T. Grant, D. Maclachlan, U. Liebeskind, D. Zeidler, W. Eberhardt, E.K. Walther, W. Kwasny, H. Bender, W.E. Berdel, M. Schemper, H.J. Biersack, E. Colajori, M. Tiemann, A.L. Hotze, M. Raderer, P. Sevelda, H. Wilke, M. Djavanmard, N. Niederle, G. Hartung, B. Weidmann, T. Haferlach, U. Keilholz, D. Depisch, J. Alberty, M. Zaiac, D. Hasenclever, E. Dühmke, H. Tesch, C. Herberhold, P. Chiru, C. Scheibenbogen, L. Uharek, W. Queißer, V. Ray, K. Ridwelski, P. Brossart, H. Löffler, E. Thiel, B.-M. Harnoss, P. Diezler, A. Korfel, T. Möhler, B. Lathan

Publikováno v: Oncology Research and Treatment. 16:482-484

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6797e40dfb2b903a9235b85bd0eed5d1
https://doi.org/10.1159/000218315

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

Autor: G, Brufman, E, Colajori, N, Ghilezan, M, Lassus, A, Martoni, N, Perevodchikova, C, Tosello, D, Viaro, C, Zielinski

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 8(2)

A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a doubling of the epirubicin dose intensity.Four hundred fifty-six patients were randomised to receive either epir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::682a0cfbbbcfa91288b640e1821c81a9
https://pubmed.ncbi.nlm.nih.gov/9093717